Lucy Parsons | PharmaTimes

MHRA authorises Vumerity for multiple sclerosis patients

Lucy Parsons — Fri, 19 Nov 2021 11:15:00 +0000

Vumerity is a next-generation oral fumarate treatment for adults with relapsing-remitting multiple sclerosis

Lucy Parsons — Fri, 19 Nov 2021 11:13:00 +0000

Eligible adult patients with primary or secondary myelofibrosis will now be able to access the treatment on the NHS

Lucy Parsons — Thu, 18 Nov 2021 12:30:00 +0000

The announcement follows a positive decision from the SMC in October 2021

Lucy Parsons — Thu, 18 Nov 2021 12:28:00 +0000

The UKHSA have said that deferring the vaccine dose could help to reduce even further the small risk of heart inflammation following vaccination

Lucy Parsons — Wed, 17 Nov 2021 12:48:00 +0000

This marks the first targeted treatment for eosinophilic granulomatosis with polyangiitis (EGPA)

Lucy Parsons — Wed, 17 Nov 2021 12:46:00 +0000

This deal will see more patients having access to treatment which could prevent 21,700 strokes and 5,400 deaths

Lucy Parsons — Tue, 16 Nov 2021 12:56:00 +0000

Voluntary license agreement will allow generic versions of pill to be manufactured

Lucy Parsons — Tue, 16 Nov 2021 12:45:00 +0000

Treatment authorised for use in adults with COVID-19 who are at high-risk of progressing to severe disease

Lucy Parsons — Tue, 16 Nov 2021 12:38:00 +0000

The data was obtained by a Freedom of Information request, according to The Independent

Lucy Parsons — Mon, 15 Nov 2021 12:48:00 +0000

Epilepsy affects over 600,000 people in the UK, which is approximately one in every 100 people